Alnylam scraps trial in rare eye disorder, blaming drug price reforms

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden’s recently-enacted Inflation Reduction Act.